FY2025 EPS Forecast for Puma Biotechnology Raised by Analyst

Puma Biotechnology, Inc. (NASDAQ:PBYI) – Stock analysts at Zacks Research upped their FY2025 earnings estimates for shares of Puma Biotechnology in a research report issued to clients and investors on Tuesday, December 24th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will earn $0.26 per share for the year, up from their previous estimate of $0.22. The consensus estimate for Puma Biotechnology’s current full-year earnings is $0.31 per share. Zacks Research also issued estimates for Puma Biotechnology’s Q3 2026 earnings at $0.29 EPS and FY2026 earnings at $0.77 EPS.

Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.31 by $0.10. The company had revenue of $80.50 million for the quarter, compared to the consensus estimate of $71.32 million. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. During the same period in the previous year, the business posted $0.12 EPS.

PBYI has been the topic of several other research reports. StockNews.com cut Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Friday, December 6th. HC Wainwright reiterated a “buy” rating and set a $7.00 price objective on shares of Puma Biotechnology in a research note on Monday, December 23rd.

Puma Biotechnology Price Performance

NASDAQ:PBYI opened at $3.08 on Friday. Puma Biotechnology has a 52 week low of $2.22 and a 52 week high of $7.73. The company has a 50-day moving average of $2.97 and a 200-day moving average of $2.99. The company has a market capitalization of $151.19 million, a price-to-earnings ratio of 6.42 and a beta of 1.08. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.42.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Frazier Life Sciences Management L.P. lifted its position in shares of Puma Biotechnology by 8.7% in the second quarter. Frazier Life Sciences Management L.P. now owns 3,062,558 shares of the biopharmaceutical company’s stock valued at $9,984,000 after buying an additional 246,264 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in Puma Biotechnology by 1.4% during the 2nd quarter. Renaissance Technologies LLC now owns 1,753,013 shares of the biopharmaceutical company’s stock valued at $5,715,000 after purchasing an additional 23,600 shares during the last quarter. Great Point Partners LLC lifted its holdings in Puma Biotechnology by 10.6% during the 2nd quarter. Great Point Partners LLC now owns 1,486,544 shares of the biopharmaceutical company’s stock valued at $4,846,000 after purchasing an additional 142,916 shares during the last quarter. American Century Companies Inc. boosted its position in Puma Biotechnology by 98.5% during the second quarter. American Century Companies Inc. now owns 738,902 shares of the biopharmaceutical company’s stock worth $2,409,000 after purchasing an additional 366,653 shares during the period. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Puma Biotechnology by 6.6% in the second quarter. Dimensional Fund Advisors LP now owns 605,977 shares of the biopharmaceutical company’s stock valued at $1,975,000 after purchasing an additional 37,684 shares during the last quarter. 61.29% of the stock is currently owned by institutional investors and hedge funds.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.